Zobrazeno 1 - 9
of 9
pro vyhledávání: ''
Autor:
Alexander N. Shoushtari, Pedram Navid-Azarbaijani, Jedd D. Wolchok, Claire F. Friedman, Katherine S. Panageas, Parisa Momtaz, Margaret K. Callahan, Paul B. Chapman, Michael A. Postow
Publikováno v:
JAMA Oncology. 4:98
Importance Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response Evaluation Criteria in Solid Tumors. The trials assessed toxic effects using the
Autor:
Maheswari Senthil, John Morgan, Laurel A. Guthrie, Majed M Ramadan, Carlos A. Garberoglio, Matthew J. Selleck, Mark E. Reeves, Mayada Aljehani, Brice Jabo, Khaled Bahjri, Sharon S. Lum
Publikováno v:
JAMA Surgery. 153:60
Biologic therapy (BT) (eg, bevacizumab or cetuximab) is increasingly used to treat metastatic colorectal cancer (mCRC). Recent investigations have suggested that right- or left-sided primary tumor origin affects survival and response to BT.To evaluat
Autor:
Soo Kien Lo, Rebecca Dent, Wen Hsin Koo, Li-Lian Kwok, Raymond Ng, Wen Yee Chay, Marie Loh, Chee Kian Tham, Nicholas Syn, Nan Soon Wong, Sili Tan, King Xin Koh, Richie Chuan Teck Soong, John Whay Kuang Chia, Yoon Sim Yap, Su Pin Choo, Han Chong Toh, Zuan Yu Mok
Publikováno v:
JAMA Oncology. 3:1538
Importance Hand-foot syndrome (HFS) is a common adverse effect of capecitabine treatment. Objective To compare the incidence and time to onset of grade 2 or greater HFS in patients receiving pyridoxine vs placebo and to identify biomarkers predictive
Autor:
Gaurav Goyal, Timothy G. Call, Ronald S. Go, William J. Hogan, Mark R. Litzow, Mithun Vinod Shah
Publikováno v:
JAMA Oncology. 3:1253
Importance While cladribine is best known for the treatment of hairy cell leukemia and other lymphoid cancers, it also has activity against myeloid neoplasms, such as Erdheim-Chester disease (ECD). Objective To assess the efficacy of cladribine (2-ch
Autor:
Kouros Owzar, Robert G. Maki, Jonathan A. Fletcher, Margaret von Mehren, George D. Demetri, Robert S. Benjamin, John Crowley, Charles D. Blanke, Martin E. Blackstein, Christopher L. Corless, Ernest C. Borden, Dennis A. Priebat, Laurence H. Baker, William D. Tap, Christopher W. Ryan, Cathryn Rankin, Michael Heinrich
Publikováno v:
JAMA Oncology. 3:944
Importance After identification of activating mutations of the KIT gene in gastrointestinal stromal tumor (GIST)—the most common sarcomaof the gastrointestinal tract—a phase 2 study demonstrated efficacy of imatinib mesylate in patients with meta
Autor:
Julie A. Price Hiller, Vincent Houe, Dennis J. Slamon, Zev A. Wainberg, Alberto Sobrero, Karen E. Mulder, Shukui Qin, Sheryl Koski, Karen King, J. Randolph Hecht, Michael P. Chu, Jennifer L. Spratlin, Andrew Scarfe, Michael B. Sawyer, Karen Afenjar, Paulo M. Hoff, Yung-Jue Bang, Yingjie J. Huang, Saba Khan-Wasti, Neil Chua
Publikováno v:
JAMA Oncology. 3:767
Capecitabine is an oral cytotoxic chemotherapeutic commonly used across cancer subtypes. As with other oral medications though, it may suffer from drug interactions that could impair its absorption.To determine if gastric acid suppressants such as pr
Autor:
Jean-Robert Harle, Xavier Dufour, Anne-Emmanuelle Fargeton, César Cartier, Patrick Dessi, Sophie Dupuis-Girod, Alexis Ambrun, Evelyne Decullier, Sophie Rivière, Sandra Blivet, Frédéric Faure, Adeline Roux, Justin Michel, Thierry Chinet, Bettina Colombet, Brigitte Gilbert-Dussardier, Valentine Bréant, P. Lacombe, Jean-Hugues Blondel
Publikováno v:
JAMA. 316:934
Background Epistaxis is the most frequent and disabling manifestation of hereditary hemorrhagic telangiectasia (HHT). The efficacy of intravenous bevacizumab (an anti-vascular endothelial growth factor monoclonal antibody) for epistaxis has been show
Publikováno v:
JAMA Otolaryngology–Head & Neck Surgery. 142:898
Importance Since their discovery in the 1970s, taxanes have maintained widespread clinical use in solid tumors, including squamous cell carcinoma of the head and neck (SCCHN), but SCCHN remains a difficult malignancy to treat, often requiring a multi
Autor:
Susan Dent, Melanie Quintana, Margaret J. Foster, Anna McGlothlin, Karen A. Gelmon, Christine Brezden-Masley, Jean Francois Boileau, Scott M. Berry, Melissa Olinger, Alexander H.G. Paterson, Stephen Chia, Donald A. Berry, Daniel Rayson, Kristine Broglio
Publikováno v:
JAMA Oncology. 2:751
Importance The expense and lengthy follow-up periods for randomized clinical trials (RCTs) of adjuvant systemic therapy in breast cancer make them impractical and even impossible to conduct. Randomized clinical trials of neoadjuvant systemic therapy